News & Events
ASX Gets Hip To Portland Float
21 / 12 / 2005
Helen Schuller, Australian Biotechnology News Hip replacement specialist Portland Orthopaedics (ASX:PLD) has listed on the ASX today at AUD$0.28, three cents above its issue price of $0.25. "We are very excited," said Portland managing director David Sekel. "The…
OPAL Therapeutics Inc, Immunotherapy Start Up, Raises $US6m Series A to target HIV and Hepatitis C.
19 / 12 / 2005
Opal Therapeutics Inc., an immunotherapy development company targeting HIV and Hepatitis C, raises $6 million Series A financing. The company raised the funds from an international syndicate led by GBS Venture Partners, Melbourne, Australia. Other members of…
Bronchitoltm European Cystic Fibrosis Study Commences
16 / 12 / 2005
Pharmaxis Ltd (ASX:PXS; NASDAQ: PXSL) announced today that a Phase II clinical trial in patients with cystic fibrosis has commenced its dosing phase. The study, which aims to determine the benefits of Bronchitol in children also receiving the market leading treatment, rhDNase, is being…
Cogstate Placement to Increase Sales Resources
15 / 12 / 2005
Share Placement CogState Limited (ASX:CGS) is pleased to announce that the company has placed 3 million fully paid ordinary shares at an issue price of A$0.10 per share. The placement has been arranged by Taylor Collison Limited ("Taylor Collison")…
CogState Accelerates Portfolio Development with A$1.28m Pfizer Deal
15 / 12 / 2005
Key points: Non-dilutive funding of up to A$1.28 million over 3 years Acceleration of cognitive test portfolio development Increased portfolio of specialist cognitive tests Potential for increased near-term revenue in 2006 CogState Ltd…
U.S. Phase Iii Aridol Trial Enrols First Patient
14 / 12 / 2005
Pharmaxis Ltd (ASX:PXS NASDAQ:PXSL) is pleased to announce that the Aridol Phase III clinical trial in patients with suspected asthma has enrolled its first patients. The trial is designed to compare the sensitivity and specificity of Aridol (mannitol) to identify exercise induced…
Sunshine Heart Completes $3.3 million Capital Raising
13 / 12 / 2005
Key points: - Sunshine Heart Inc completes a private placement to institutional and sophisticated investors raising approximately $3.3 million at 19.5 cents per share. - The proceeds will be applied to the clinical trial in Australia and to progress…
Chief Operating Officer Appointed by Sunshine Heart
05 / 12 / 2005
Key points: - Victor Windeyer has been appointed Chief Operating Officer (COO) of Sunshine Heart, Inc. - Victor has extensive executive experience in the medical device field, including responsibilities at Ventracor, Cochlear and Invetech., - The COO…
Cortical Pty Ltd Presents MIF Antagonist Data at American College of Rheumatology 2005 Annual Scientific Meeting
01 / 12 / 2005
Melbourne-based discovery research and development company Cortical Pty Ltd has recently presented pre-clinical data on its anti-inflammatory compound COR100140 at the 2005 ACR/AHRP Annual Scientific Meeting in San Diego, California, November 12-17, 2005. Cortical has…
Bronchitol Granted Orphan Drug Status in Europe
14 / 11 / 2005
Pharmaxis Ltd (ASX:PXS, NASDAQ:PXSL) announced today that the European Medicines Agency (EMEA) has granted Orphan designation to the company's product BronchitolT, for the treatment of cystic fibrosis. Orphan designation has been granted on the basis of Bronchitol's potential…
Hip and Knee Replacements Company Portland Orthopaedics to Raise $5M in New IPO
14 / 11 / 2005
1500 Implants Already as Portland Raises Funds to Accelerate Commercialisation Sydney, Australia: Portland Orthopaedics, a developer and manufacturer of specialist hip and knee joint replacements is raising $5 million in a new…
Sunshine Heart Prepares for First Clinical Trial in Australia
08 / 11 / 2005
Key points: - Sunshine Heart, Inc. receives Ethics Committee Approval from Southern Health Monash Medical Centre, Clayton Victoria, to extend its clinical trial for the C-Pulse heart assist implant. - Southern Health is one of two Victorian hospitals expected to…
PHARMAXIS LTD ANNOUNCES PRICING OF GLOBAL CAPITAL RAISING
08 / 11 / 2005
ASX/ NASDAQ Media release SYDNEY, Australia - Pharmaxis Ltd announced today the pricing of an underwritten public offering of 1,300,000 American Depositary Shares ("ADSs") at a price of US$24.16 per ADS. Each ADS represents 15 ordinary shares in Pharmaxis. CIBC World Markets…
Sunshine Heart Appoints Clinical Affairs Manager
01 / 11 / 2005
Sydney: Sunshine Heart (ASX: SHC) has appointed Ruth Flynn to the newly created role of Clinical Affairs Manager to progress the company's clinical trial program in Australia and New Zealand. Chief Executive Officer of Sunshine Heart Inc. Donald Rohrbaugh said: "Ms Flynn is…
Promising Results From C-Pulse Heart Assist Device Trials
26 / 10 / 2005
Sydney, Australia: Dr Paget Milsom, the principal investigator of the CPulse heart assist device, today presented new data supporting that C-Pulse as a promising option for patients with heart failure at the Annual Scientific Meeting of the Australasian Society of…
Pharmaxis Ltd Announces Global Capital Raising
26 / 09 / 2005
SYDNEY, Australia - Pharmaxis Ltd (ASX: PXS, Nasdaq: PXSL) announced that it had today filed a registration statement with the US Securities and Exchange Commission for the sale of 21,000,000 ordinary shares in the form of 1,400,000 American Depositary Shares (ADSs) in…
Enrolment Commenced in Aridoltm Copd Study
15 / 09 / 2005
Pharmaxis (ASX:PXS; NASDAQ: PXSL) is pleased to announce that its AridolTM Phase II clinical trial in 140 patients with chronic obstructive pulmonary disease (COPD) has enrolled its first patient. The study is designed to assess the ability of Aridol to predict the usefulness of inhaled…
CogState Signs Agreement to Acquire Canadian Software Test Product to Market to the Clinical Trials Market
15 / 09 / 2005
Melbourne based healthcare IT company, CogState Ltd (ASX:CGS), announced today it signed an agreement with a Montreal, Canada based company to acquire a Voice Analysis (VA) software product which can identify symptoms of Parkinson's Disease. The software may also have applications in…
CogState Announces Restructuring
15 / 09 / 2005
In recognition of accelerating growth in revenues, CogState Ltd (ASX:CGS) announces today that they have decided to implement the following important realignments: 1. CogState will focus on its clinical technology core business; selling clinical IT software tests to…
Novasys Medical Announces New Chief Medical Officer, Charles S. Carignan, M.D.
08 / 09 / 2005
Leader in clinical and medical affairs from Boston Scientific and Conceptus Newark, Calif., - Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that Charles S. Carignan, M.D., has joined the company as Chief Medical Officer and Vice…